

## Supplementary Material

# Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1 $\alpha$ /PI3K/AKT Signaling Pathways in Breast Cancer


Yuxin Zhou <sup>1</sup>, Minru Liao <sup>1</sup>, Zixiang Li <sup>2</sup>, Jing Ye <sup>1</sup>, Lifeng Wu <sup>1</sup>, Yi Mou <sup>1</sup>, Leilei Fu <sup>2\*</sup> and Yongqi Zhen <sup>1\*</sup>

<sup>1</sup> Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China; charlotte\_zyx@outlook.com (Y.Z.); 15680965456@163.com (M.L.)

<sup>2</sup> Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China; li69010@163.com (Z.L.); scuyj0222@163.com (J.Y.); 18482273923@163.com (L.W.); skayhy@163.com (Y.M.)

\* Correspondence: leilei\_fu@swjtu.edu.cn (L.F.); zhenyongqi@scu.edu.cn (Y.Z.).

Supplementary Figure S1



**Figure S1. Cell viability of flubendazole and paclitaxel on normal breast cells (MCF-10A).** Cell viabilities were measured by MTT assay. Data are expressed as mean  $\pm$  SEM. All data were representative of at least three independent experiments. Statistical significance compared with respective control groups.